Xp11 Translocation Carcinoma
1 clinical trials · Condition
◉ Watch Xp11 Translocation Carcinoma
| Record | Firm | Date |
|---|---|---|
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (NCT03177239) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-10-19 |
Track Xp11 Translocation Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.